The U.S. Food and Drug Administration have made moves to increase generics competition to combat rising drug prices.
The FDA also posted a list of unprotected branded drugs that are not facing generic competition. According to the regulatory body, this is in order to increase transparency and to spur more generic drug development. This effort includes fast-tracking reviews of abbreviated new drug applications until there are three approved generics for a given drug. According to the agency, data finds that consumers see significant price reductions when there are multiple FDA-approved generics available.
Read the FDA release